Dr. Semb has received consulting fees, speaking fees, and/or honoraria from Merck/Schering-Plough, Abbott, Bristol-Myers Squibb, Wyeth/Pfizer, and Roche (less than $10,000 each).
Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease†
Version of Record online: 27 AUG 2012
Copyright © 2012 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 64, Issue 9, pages 2836–2846, September 2012
How to Cite
Semb, A. G., Kvien, T. K., DeMicco, D. A., Fayyad, R., Wun, C.-C., LaRosa, J. C., Betteridge, J., Pedersen, T. R. and Holme, I. (2012), Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis & Rheumatism, 64: 2836–2846. doi: 10.1002/art.34524
ClinicalTrials.gov identifiers: NCT00159835 and NCT00327691.
- Issue online: 27 AUG 2012
- Version of Record online: 27 AUG 2012
- Accepted manuscript online: 10 MAY 2012 01:41PM EST
- Manuscript Accepted: 24 APR 2012
- Manuscript Received: 14 SEP 2011
- South-Eastern Regional Health Authority of Norway
Additional Supporting Information may be found in the online version of this article.
|ART_34524_sm_SupplTable1.doc||46K||Supplementary Table 1|
|ART_34524_sm_SupplTable2.doc||56K||Supplementary Table 2|
|ART_34524_sm_SupplTable3.doc||33K||Supplementary Table 3|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.